Modulation of P-glycoprotein activity by the substituted quinoxalinone compound QA3 in adriamycin-resistant K562/A02 cells

Pharmacological Reports

Volumn 62, Issue 2, 2010, Pages 333-342

  Sun, Li Rui ^a,b   Zhong, Julia Li ^c   Cui, Shu Xiang ^d   Li, Xun ^a   Ward, Stephen Geoffrey ^e   Shi, Yan Qiu ^a   Zhang, Xiao Fan ^a   Cheng, Yan Na ^a   Gao, Jian Jun ^a   Qu, Xian Jun ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c CHONGQING UNIVERSITY   (China)

^d University of Bath   (United Kingdom)

^e SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

3 dimethyl 1H quinoxalin 2 ones QA3; Apoptosis; ATP; ATPase; Caspases; Compound of the substituted 1; Multidrug resistance (MDR); P glycoprotein (P gp); PKC

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; CASPASE 3; CASPASE 9; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROCASPASE 9; PROTEIN KINASE C; QUINOXALINONE COMPOUND QA3; UNCLASSIFIED DRUG; CASPASE; MULTIDRUG RESISTANCE PROTEIN; QUINOXALINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN K 562; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; MICROSOME; PROTEIN HYDROLYSIS; PROTEIN SYNTHESIS INHIBITION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; K562 CELL LINE; METABOLISM; MULTIDRUG RESISTANCE; PHYSIOLOGY;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; APOPTOSIS; CASPASES; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; K562 CELLS; P-GLYCOPROTEIN; PROTEIN KINASE C; QUINOXALINES;

EID: 77953328108     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70273-5     Document Type: Article

References (45)

1. Al-Shawi MK, Polar MK, Omote H, Figler RA: Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. J Biol Chem, 2003, 278, 52629-52640.
2. Avendano C, Menendez JC: Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem, 2002, 9, 159-193.
3. Barakat S, Gayet L, Dayan G, Labialle S, Lazar A, Oleinikov V, Coleman AW, Baggetto LG: Multidrugresistant cancer cells contain two populations of Pglycoprotein with differently stimulated P-gp ATPase activities: evidence from atomic force microscopy and biochemical analysis. Biochem J, 2005, 388, 563-571.
4. Bielawski K, Bielawska A, Słodownik T, Bołkun-Skórnicka U, Muszyńska A: Proline-linked nitrosoureas as prolidase-convertible prodrugs in human breast cancer cells. Pharmacol Rep, 2008, 60, 171-182.
5. Bucher K, Besse CA, Kamau SW, Wunderli-Allenspach H, Krämer SD: Isolated rafts from adriamycin-resistant P388 cells contain functional ATPases and provide an easy test system for P-glycoprotein-related activities. Pharm Res, 2005, 22, 449-57.
6. Chen H, Wang J, Zhang J, Wang Y, Cao B, Bai S, Yu PF, Bi W, Xie W: L1EPO, a novel podophyllotoxin derivative overcomes P-glycoprotein-mediated multidrug resistance in K562/A02 cell line. Biol Pharm Bull, 2009, 32, 609-613.
7. Dubielecka PM, Jaźwiec B, Potoczek S, Wróbel T, Miłoszewska J, Haus O, Kuliczkowski K, Sikorski AF: Changes in spectrin organisation in leukaemic and lymphoid cells upon chemotherapy. Biochem Pharmacol, 2005, 69, 73-85.
8. Fong WF, Shen XL, Globisch C, Wiese M, Chen GY, Zhu GY, Yu ZL Tse AK, Hu YJ: Methoxylation of 3',4'-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells. Bioorg Med Chem, 2008, 16, 3694-3703.
9. García MG, Alaniz LD, Cordo Russo RI, Alvarez E, Hajos SE: PI3K/Akt inhibition modulates multidrug resistance and activates NF-kB in murine lymphoma cell lines. Leukemia Res, 2009, 33, 288-296.
10. Higgins CF, Linton KJ: The ATP switch model for ABC transporters. Nat Struct Mol Biol, 2004, 10, 918-926.
11. Huang M, Jin J, Sun H, Liu GT: Reversal of P-glycoproteinmediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother Pharmacol, 2008, 62, 1015-1026.
12. Idriss H, Urquidi V, Basavappa S: Selective modulation of P-glycoprotein's ATPase and anion efflux regulation activities with PKC a and PKC e in Sf9 cells. Cancer Chemother Pharmacol, 2000, 46, 287-292.
13. Jones PM, George AM: Opening of the ADP-bound active site in the ABC transporter ATPase dimer: evidence for a constant contact, alternating sites model for the catalytic cycle. Proteins, 2009, 75, 387-396.
14. Lawrence DS, Copper JE, Smith CD: Structure-activity studies of substituted quinoxalinones as multiple-rugresistance antagonists. J Med Chem, 2001, 44, 594-601.
15. Lee BD, French KJ, Zhuang Y, Smith CD: Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008. Oncol Res, 2003, 14, 49-60.
16. Lee BD, Li Z, French KJ, Zhuang Y, Xia Z, Smith CD: Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. J Med Chem, 2004, 47, 1413-1422.
17. Li X, Sun B, Zhu CJ, Yuan HQ, Shi YQ, Gao J, Li SJ, Lou HX: Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells. Toxicol In Vitro, 2009, 23, 29-36.
18. Li X, Wang D, Wu J, Xu W: Synthesis of substituted 1,3-dimethyl-1H-quinoxalin-2-ones from aniline derivatives. Heterocycles, 2005, 65, 2741-2751.
19. Li Y, Tanaka K, Li X, Okada T, Nakamura T, Takasaki M, Yamamoto S, Oda Y, Tsuneyoshi M, Iwamoto Y: Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells. Int J Cancer, 2007, 121, 1212-1218.
20. Linton KJ: Structure and function of ABC transporters. Physiology (Bethesda), 2007, 22, 122-130.
21. Linton KJ, Higgins C: Structure and function of ABC transporters: the ATP switch provides flexible control. Pflugers Arch, 2007, 453, 555-567.
22. Loo TW, Bartlett MC, Clarke DM: Nucleotide binding, ATP hydrolysis, and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments. Biochemistry, 2007, 46, 9328-9336.
23. Lopes EC, Garcia M, Benavides F, Shen J, Conti CJ, Alvarez E, Hajos SE: Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotype. Leukemia Res, 2003, 27, 413-423.
24. Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C et al.: Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res, 2008, 68, 9809-9816.
25. Mantovani I, Cappellini A, Tazzari PL, Papa V, Cocco L, Martelli AM: Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells. J Cell Physiol, 2006, 207, 836-844.
26. Marguerite V, Beri-Dexheimer M, Ortiou S, Guéant JL, Merten M: Cobalamin potentiates vinblastine cytotoxicity through downregulation of mdr-1 gene expression in HepG2 cells. Cell Physiol Biochem, 2007, 20, 967-976.
27. Marquenet E, Richet E: How integration of positive and negative regulatory signals by a STAND signaling protein depends on ATP hydrolysis. Mol Cell, 2007, 28, 187-199.
28. Matsunaga T, Kose E, Yasuda S, Ise H, Ikeda U, Ohmori S: Determination of P-Glycoprotein ATPase activity using luciferase. Biol Pharm Bull, 2006, 29, 560-564.
29. Melin P, Norez C, Callebaut I, Becq F: The glycine residues G551 and G1349 within the ATP-binding cassette signature motifs play critical roles in the activation and inhibition of cystic fibrosis transmembrane conductance regulator channels by phloxine. J Membr Biol, 2005, 208, 203-212.
30. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA et al.: In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res, 2001, 61, 749-758.
31. O'Brian CA, Ward NE, Stewart JR, Chu F: Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer - an evolving story. Cancer Metastasis Rev, 2001, 20, 95-100.
32. Okutucu B, Dincer A, Habib O, Zihnioglu F: Comparison of five methods for determination of total plasma protein concentration. J Biochem Biophys Methods, 2007, 70, 709-711.
33. Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR: P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Biochem Pharmacol, 2006, 72, 293-307.
34. Pérez-Victoria JM, Di Pietro A, Barron D, Ravelo AG, Castanys S, Gamarro F: Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents. Curr Drug Targets, 2002, 3, 311-333.
35. Sauna ZE, Smith MM, Müller M, Kerr KM, Ambudkar S: The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr, 2001, 33, 481-491V.
36. Sekhon BK, Roubin RH, Tan A, Chan WK, Sze DM: High-throughput screening platform for anticancer therapeutic drug cytotoxicity. Assay Drug Dev Technol, 2008, 6, 711-721.
37. Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH et al.: Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther, 2008, 324, 95-102.
38. Shi YQ, Qu XJ, Liao YX, Xie CF, Cheng YN, Li S, Lou HX: Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells. Eur J Pharmacol, 2008, 584, 66-71.
39. Sprague RS, Hanson MS, Achilleus D, Bowles EA, Stephenson AH, Sridharan M, Adderley S et al.: Rabbit erythrocytes release ATP and dilate skeletal muscle arterioles in the presence of reduced oxygen tension. Pharmacol Rep, 2009, 61, 183-190.
40. Sukumaran SK, Prasadarao NV: Regulation of protein kinase C in Escherichia coli K1 invasion of human brain microvascular endothelial cells. J Biol Chem, 2002, 277, 12253-12262.
41. Sun LR, Li X, Cheng YN, Yuan HY, Chen MH, Tang W, Ward SG, Qu XJ: Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells. Biomed Pharmacother, 2009, 63, 202-208.
42. Wang E, Casciano CN, Clement RP, Johnson WW: The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res, 2001, 61, 7525-7529.
43. Wei YL, Xu L, Liang Y, Xu XH, Zhao XY: Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo. Acta Pharmacol Sin, 2009, 30, 451-457.
44. Zhang S, Morris ME: Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-lycoproteinmediated transport. J Pharmacol Exp Ther, 2003, 304, 1258-1267.
45. Zhen YZ, Lin YJ, Shang BY, Zhen YS: Enediyne lidamycin induces apoptosis in human multiple myeloma cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase. Int J Hematol, 2009, 90, 44-51.